Literature DB >> 15781393

Targeting the gatekeeper residue in phosphoinositide 3-kinases.

Peter J Alaimo1, Zachary A Knight, Kevan M Shokat.   

Abstract

A single residue in the ATP binding pocket of protein kinases-termed the gatekeeper-has been shown to control sensitivity to a wide range of small molecule inhibitors (Chem. Biol.2004, 11, 691; Chem. Biol.1999, 6, 671). Kinases that possess a small side chain at this position (Thr, Ala, or Gly) are readily targeted by structurally diverse classes of inhibitors, whereas kinases that possess a larger residue at this position are broadly resistant. Recently, lipid kinases of the phosphoinositide 3-kinase (PI3-K) family have become the focus of intense research interest as potential drug targets (Chem. Biol.2003, 10, 207; Curr. Opin. Pharmacol.2003, 3, 426). In this study, we identify the residue that corresponds structurally to the gatekeeper in PI3-Ks, and explore its importance in controlling enzyme activity and small molecule sensitivity. Isoleucine 848 of p110alpha was mutated to alanine and glycine, but the mutated kinase was found to have severely impaired enzymatic activity. A structural bioinformatic comparison of this kinase with its yeast orthologs identified second site mutations that rescued the enzymatic activity of the I848A kinase. To probe the dimensions of the gatekeeper pocket, a focused panel of analogs of the PI3-K inhibitor LY294002 was synthesized and its activity against gatekeeper mutated and wild-type p110alpha was assessed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781393     DOI: 10.1016/j.bmc.2005.02.021

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 2.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

3.  Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases.

Authors:  Cynthia M Chio; Xiaoling Yu; Anthony C Bishop
Journal:  Bioorg Med Chem       Date:  2015-03-17       Impact factor: 3.641

4.  Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.

Authors:  Hakryul Jo; Pang-Kuo Lo; Yitang Li; Fabien Loison; Sarah Green; Jake Wang; Leslie E Silberstein; Keqiang Ye; Hexin Chen; Hongbo R Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-04       Impact factor: 11.205

5.  Allele-specific inhibition of divergent protein tyrosine phosphatases with a single small molecule.

Authors:  Xin-Yu Zhang; Vincent L Chen; Mari S Rosen; Elizabeth R Blair; Anna Mari Lone; Anthony C Bishop
Journal:  Bioorg Med Chem       Date:  2008-07-24       Impact factor: 3.641

6.  Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae.

Authors:  Joseph I Kliegman; Dorothea Fiedler; Colm J Ryan; Yi-Fan Xu; Xiao-Yang Su; David Thomas; Max C Caccese; Ada Cheng; Michael Shales; Joshua D Rabinowitz; Nevan J Krogan; Kevan M Shokat
Journal:  Cell Rep       Date:  2013-12-19       Impact factor: 9.423

7.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

8.  Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.

Authors:  Eli R Zunder; Zachary A Knight; Benjamin T Houseman; Beth Apsel; Kevan M Shokat
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

9.  Structure prediction and validation of the ERK8 kinase domain.

Authors:  Angela Strambi; Mattia Mori; Matteo Rossi; David Colecchia; Fabrizio Manetti; Francesca Carlomagno; Maurizio Botta; Mario Chiariello
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization.

Authors:  Jonathan H Clarke; Robin F Irvine
Journal:  Biochem J       Date:  2013-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.